Table 3.
Summary of SWIFT performance ranking metrics
| Cohen (2006) [6] | Matwin (2010) [28] | Cohen (2008/11) [29, 30] | SWIFT-Review (25 trials) | |
|---|---|---|---|---|
| WSS@95 [proportion of studies screened to achieve 95 % recall] | ||||
| PFOA/PFOS and immunotoxicity | N/A | N/A | N/A | 0.805 [0.145] |
| Bisphenol A (BPA) and obesity | N/A | N/A | N/A | 0.752 [0.198] |
| Transgenerational inheritance of health effects | N/A | N/A | N/A | 0.714 [0.236] |
| Fluoride and neurotoxicity in animal models | N/A | N/A | N/A | 0.870 [0.080] |
| Neuropathic pain | N/A | N/A | N/A | 0.691 [0.259] |
| SWIFT-Review mean | 0.766 [0.184] | |||
| Skeletal muscle relaxants | 0.000 [0.950] | 0.265 [0.685] | 0.374 [0.576] | 0.556 [0.394] |
| Opioids | 0.133 [0.817] | 0.554 [0.396] | 0.364 [0.586] | 0.826 [0.124] |
| Antihistamines | 0.000 [0.950] | 0.149 [0.801] | 0.236 [0.714] | 0.137 [0.813] |
| ADHD | 0.680 [0.270] | 0.622 [0.328] | 0.526 [0.424] | 0.793 [0.157] |
| Triptans | 0.034 [0.916] | 0.274 [0.676] | 0.346 [0.604] | 0.412 [0.538] |
| Urinary incontinence | 0.261 [0.689] | 0.296 [0.654] | 0.432 [0.518] | 0.530 [0.420] |
| Ace inhibitors | 0.566 [0.384] | 0.523 [0.427] | 0.733 [0.217] | 0.801 [0.149] |
| Nonsteroidal anti-inflammatory | 0.497 [0.453] | 0.528 [0.422] | 0.672 [0.278] | 0.730 [0.220] |
| Beta blockers | 0.284 [0.666] | 0.367 [0.583] | 0.465 [0.485] | 0.428 [0.522] |
| Proton pump inhibitors | 0.277 [0.773] | 0.229 [0.721] | 0.328 [0.622] | 0.378 [0.572] |
| Estrogens | 0.183 [0.767] | 0.375 [0.575] | 0.414 [0.536] | 0.471 [0.479] |
| Statins | 0.247 [0.803] | 0.315 [0.635] | 0.491 [0.459] | 0.436 [0.514] |
| Calcium-channel blockers | 0.122 [0.828] | 0.234 [0.716] | 0.430 [0.520] | 0.448 [0.502] |
| Oral hypoglycemics | 0.090 [0.860] | 0.085 [0.865] | 0.136 [0.814] | 0.117 [0.833] |
| Atypical antipsychotics | 0.141 [0.809] | 0.206 [0.744] | 0.170 [0.780] | 0.251 [0.699] |
| Mean (Cohen benchmark) | 0.234 [0.716] | 0.335 [0.615] | 0.408 [0.542] | 0.488 [0.462] |
| SWIFT-Review grand mean | 0.540 [0.410] | |||
Metrics shown are the WSS@95 and (in brackets) the proportion of studies screened to achieve 95 % recall. When applicable, bold text indicates the method with the highest performance (highest WSS) for each dataset